TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer (TORCH)
An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer
Sponsor: National Cancer Institute, Naples
A PHASE3 clinical study on Advanced Non-Small Cell Lung Cancer, this trial is completed. The trial is conducted by National Cancer Institute, Naples and has accumulated 7 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Sep 2017 [monthly]
Completed PHASE3
First recorded
Dec 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute, Naples
- Princess Margaret Hospital, Canada
- San Giuseppe Moscati Hospital
- University of Alberta
- University of Campania Luigi Vanvitelli
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alba, Italy , Asti, Italy , Aviano, Italy , Bari, Italy , Belcolle, Italy , Benevento, Italy , Brindisi, Italy , Calgary, Canada , Campobasso, Italy , Carpi, Italy and 52 more locations